A Phase I Randomized Study in Healthy Adults to Assess the Safety, Reactogenicity and Immunogenicity of Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Trial Profile

A Phase I Randomized Study in Healthy Adults to Assess the Safety, Reactogenicity and Immunogenicity of Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Influenza A virus H7N9 vaccines (Primary) ; MEDI 9287 (Primary) ; MF 59
  • Indications Influenza A virus H7N9 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Feb 2017 Planned End Date changed from 1 Nov 2016 to 30 Jun 2018.
    • 16 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 30 Jun 2018.
    • 14 Jul 2016 Planned End Date changed from 1 Aug 2015 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top